Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial

Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.

Source: CancerNetwork - April 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news